Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. by Corrocher, G. et al.
Comparative effect of tacrolimus
0.1% ointment and clobetasol
0.05% ointment in patients with
oral lichen planus
Corrocher G, Di Lorenzo G, Martinelli N, Mansueto P, Biasi D, Nocini PF, Lombardo
G, Fior A, Corrocher R, Bambara LM, Gelio S, Pacor ML. Comparative effect of
tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen
planus. J Clin Periodontol 2007; 35: 244–249. doi: 10.1111/j.1600-051X.2006.01191.x.
Abstract
Background: Oral lichen planus (OLP) is considered to be an autoimmune disease
of unknown aetiology that affects the mucosae, especially the oral cavity.
Objective: We compared tacrolimus 0.1% ointment and clobetasol 0.05% ointment
for the treatment of OLP.
Patients and Methods: A total of 32 patients (20 females and 12 males; all white,
Italian origin, mean age of 43.6  18.4 years; 16 patients per treatment group) were
treated with tacrolimus or clobetasol ointment for 4 weeks in a randomized,
double-blind, clinical trial. Pain severity, burning sensation, and mucosal lesion
extension were assessed using a four-point scale.
Results: At the end of the treatment period, symptom scores were significantly lower
in the tacrolimus group than in the clobetasol group.
Conclusion: The results of this study suggest that tacrolimus 0.1% ointment is more
effective than clobetasol propionate 0.05% ointment in the treatment of OLP.
However, other studies are needed to confirm the effectiveness of this treatment before
it can be recommended for use in clinical practice.
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Lichen planus is a chronic inflammatory
disorder of cutaneous and mucosal tis-
sues that is estimated to affect 0.5–2.2%
of the general population (DeRossi
& Ciarrocca 2005). Oral lichen planus
(OLP) is considered to be an auto-
immune disease of unknown aetiology
in which epithelial cells are recognized
as foreign due to changes in cell surface
antigenicity (Edwards & Kelsch 2002).
In contrast to cutaneous lichen planus,
in which the clinical course is often mild
and resolves within 2 years, mucosal
OLP tends to follow a more chronic
course and is often accompanied by
acute exacerbations characterized by
pain and burning sensations with consid-
erable loss of quality of life (Dissemond
2004). An epidemiological study de-
monstrated that women suffer from
OLP more frequently (75%) than men
(25%), and that the disease is more
frequent in people over 40 years of age
(Eisen 2002). The diagnosis of OLP is
based on a combination of characteristic
clinical findings and histopathological
examination. Three different forms
of OLP are currently described: (1)
a hyperkeratotic (white) form that is often
asymptomatic, (2) an atrophic or erythe-
matous (red) form that is associated with
mild to moderate symptoms, and (3)
an erosive or ulcerative (yellow) form
that usually has persistent symptoms
(Setterfield et al. 2000, de Moura Castro
Jacques et al. 2003, Eisen 2003, Lodi
et al. 2005).
Patients with symptomatic OLP often
require intensive therapy to reduce the
signs and symptoms of this painful and
disabling inflammatory disease (Chan
et al. 2000). When pain and burning sen-
sations are severe, therapeutic options
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include high-potency topical corticos-
teroids; systemic corticosteroids may
be indicated in patients whose condition
is unresponsive to topical cortico-
steroids. For such patients, other treat-
ments include immunosuppressive drugs
such as cyclosporine, tacrolimus, and
retinoids (Sloberg et al. 1983, Rozycki
et al. 2002, Carbone et al. 2003, Conrotto
et al. 2006).
The aim of this randomized, double-
blind, 4-week clinical trial was to com-
pare treatment efficacy and tolerability
of topical tacrolimus 0.1% ointment
with topical clobetasol propionate
0.05% ointment in adults with OLP.
Patients and Methods
Patients
This study was approved by the Human
Subjects Committee of the Institutional
Review Board of the Dipartimento di
Medicina Clinica e Sperimentale, Uni-
versita` di Verona, Verona, Italy, where
the study was conducted. All patients
provided written informed consent to
participate, in compliance with the insti-
tutional policy of Policlinico ‘‘GB Rossi’’
of Verona, Italy. The study was con-
ducted in accordance with the principles
of the Declaration of Helsinki (World
Medical Association Declaration of
Helsinki 1989) and Good Clinical Prac-
tice (European Agency for the Evalua-
tion of Medicinal Products 2002).
Inclusion and exclusion criteria
Patients aged 418 years were selected
from the electronic medical records of
the Dipartimento di Medicina Clinica e
Sperimentale, Universita` di Verona,
Verona, Italy on the basis of a clinical
history of moderate to severe OLP. The
clinical diagnosis was confirmed histo-
logically in all patients by one of the
investigators (G. C.) using the following
features of OLP: (1) liquefaction of oral
epithelium, (2) apoptosis of keratino-
cytes, (3) focal areas of hyperkerati-
nized epithelium, and (4) presence of a
dense band-like lymphocytic infiltrate at
the interface between the epithelium and
connective tissue (Edwards & Kelsch
2002). The exclusion criteria were pre-
sence of skin and/or genital lesions,
histopathologic signs of dysplasia, treat-
ment with drugs that may induce liche-
noid reactions, previous treatment with
systemic corticosteroids, immunosup-
pressant therapy, topical glucocorticoids
or tacrolimus within the previous 8 weeks,
chronic liver disease, immune system
dysfunction, haematological disease,
pregnancy, and lactation.
Study design and medications (Fig. 1)
After screening, all patients underwent a
2-week wash-out period in which no
therapy was administered. After this
period, patients were randomly assigned
in a 1:1 ratio using computer randomi-
zation (StatsDirect Ltd., Cheshire, UK)
to receive 2ml of tacrolimus 0.1% oint-
ment (equivalent to 0.2mg of tacroli-
mus) or 2ml of clobetasol propionate
0.05% ointment (equivalent to 1mg of
clobetasol) four times daily for 4 weeks.
All therapy was discontinued after
4 weeks. Tacrolimus was prepared by
a pharmacist (S. G.) at the Servizio Farm-
acia of the Policlinico ‘‘G.B. Rossi’’ of
Verona, Italy. Clobetasol propionate
0.05% ointment was purchased from
GlaxoSmithKline, Verona, Italy. Medi-
cations were identically packaged to
maintain examiner and subject blinding.
Patients were instructed to apply the
medications using a latex glove and to
refrain from eating and drinking for
at least 30min. after application. All
patients maintained a diary throughout
the study to assess compliance with
therapy. No rescue medications were
allowed during the study. One dental
surgeon (G. C.) was responsible for
ensuring randomization, blinding, and
dispensing medications.
Assessment of efficacy of the treatment
Evaluations were performed at three
time points: (1) before treatment (base-
line), (2) 4 weeks after beginning treat-
ment, and (3) 6 weeks after beginning
treatment (2 weeks after discontinuing
treatment). All clinical evaluations were
performed by one member of the study
team (M. L. P.) who was blinded to
treatment assignment. The signs of OLP
(i.e., mucosal extension) were quantified
by this investigator using a calculated
score based on the surface extension of
mucosal lesions. This score was deter-
mined using a drawing in which the
areas of various zones of affected
mucosa were marked and expressed as
a percentage of the total oral mucosa as
previously described by Corrocher et al.
(2006). Mucosal lesion extension was
Inclusion criteria: 
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- histologically confirmed, 
moderate to severe oral 
lichen planus 
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- presence of skin and/or genital lesions 
- histopathological signs of dyplasia 
- drug-induced lichenoid reactions 
- previous therapies with immunosuppressant 
and/or systemic corticosteroid  
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FOLLOW-UP
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beginning therapy) 
3  evaluation 
(2 weeks after 
discontinuing therapy)
Fig. 1. Trial diagram.
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assessed using a four-point scale [based
on a percentage estimate of the affected
mucosa: 05 absent; 15 involvement
o5% of total mucosal surface area
(mild); 25 5–15% of total mucosal
surface area (moderate); and 35415%
of total mucosal surface area (severe)].
Pain and burning sensation were also
assessed using a four-point scale
(05 absent, 15mild, 25moderate,
and 35 severe).
Tolerability and safety assessment
The tolerability of treatments was
assessed using haematological and
biochemical testing. At baseline, at the
conclusion of treatment (4 weeks), and
at the follow-up visit (6 weeks), patients
underwent haematological testing (mea-
surement of haemoglobin concentration
and counts of red blood cells, platelets,
and white blood cells, performed with
a Technicon-H1 blood cell counter,
Bayer, Leverkusen, Germany), electro-
lyte testing (measurement of serum
sodium and potassium), kidney function
testing (serum creatinine, serum urea,
and urinary analysis), liver function
testing (serum aspartate aminotransfer-
ase, serum alanine aminotransferase,
serum alkaline phosphatase, and serum
g-glutamyl transpeptidase), and fasting
plasma glucose testing (performed with
an autoanalyser Modular AR, ISE 900
P800, Roche Diagnostics Systems,
Basel, Switzerland). Blood concentra-
tions of tacrolimus and its metabolites
were measured using a commercial kit
(Dade Behring Syva Enzyme Multiplied
Immunoassay Technique, Liederbach,
Germany) and a Cobas Integra 400
analyser (Roche Diagnostics Systems).
The lower limit of detection in the
serum was 1.5 ng/l.
Adverse events were also recorded at
each visit based on spontaneous reports
by patients, patient interview, and/or
direct observation by the investigator
(M. L. P.). The severity of adverse
events was assessed using a three-point
scale (mild, moderate, or severe) and the
relationship of each adverse event to
treatment was assessed as unrelated,
unlikely to be related, possibly related,
probably related, or almost certainly
related to study treatment.
Microbiological procedures for Candida
detection
Secondary infection with Candida spe-
cies that can exacerbate OLP symptoms
is very common in OLP patients,
especially those treated with topical
corticosteroids. Therefore, unstimulated
whole saliva from all patients was
cultured for Candida using Sabouraud
Dextrose Agar (Difco Laboratories,
Detroit, MI, USA) at baseline, at the
conclusion of treatment (4 weeks) and at
the follow-up visit (6 weeks).
Compliance
Compliance was assessed by evaluating
the unused drug at the end of the treat-
ment period and by checking the daily
diary of each patient about use of the
assigned medication.
Statistical analysis
Statistical analysis was performed with
the SPSS 13.0 software package (SPSS
Inc., Chicago, IL, USA). Severity scores
for pain, burning sensation, and mucosal
extension were considered to be ordinal
and were analysed using nonparametric
tests. The proportions of symptom
scores for each treatment group were
analysed at each time interval (baseline,
4 weeks, 6 weeks) using the Wilcoxon
signed-rank test. The Mann–Whitney
U-test was used to statistically compare
symptom scores among treatment
groups at each time interval. The pri-
mary end point was the number of
patients who achieved complete remis-
sion (severity score of 0) of symptoms/
signs. A difference of 50% in prevalence
between the two treatment groups of this
outcome was considered to be clinically
meaningful. A sample size of 32 patients
was calculated a priori for a power
of 90% to detect this difference as
determined by the Altman nomogram
(Altman 1980).
Results
A total of 32 patients (20 females and
12 males; all white, Italian origin, with
a mean age of 43.6  18.4 years;
16 patients per treatment group) were
enrolled in this study. The two treatment
groups were not statistically different
for gender distribution (tacrolimus and
clobetasol group 6/16 males) and age
(tacrolimus group mean age5 43.6 
19.3 years versus clobetasol group
mean age5 43.7  18.2 years). All
enrolled patients completed all phases
of the trial, including the 2-week follow-
up visit (100% compliance).
Table 1 gives the number and percen-
tages of patients with various severity
scores for pain, burning sensation, and
mucosal extension at baseline, at the end
of the 4-week treatment period, and at
the 2-week follow-up visit (week 6) in
each treatment group. At baseline, all
patients in both treatment groups had
pain, burning sensation, and mucosal
extension with severity scores ranging
from 2 to 3. There were no statistically
significant differences in the median
symptom scores between the tacrolimus
and clobetasol groups at baseline.
Efficacy
At the end of treatment, all patients in
the tacrolimus group had decreased
pain, burning sensation, and mucosal
extension, with a substantial proportion
of subjects achieving complete remis-
sion of symptoms/signs (68.8%, 93.7%,
and 56.3%, respectively); median
4 week scores were significantly less
than median baseline scores for these
parameters (po0.001). The improve-
ment was maintained during follow-up
(po0.001 versus baseline) for median
burning sensation and mucosal exten-
sion scores, but we found that the
median pain severity score was statisti-
cally significantly greater (po0.05)
at the 6-week visit compared with the
4-week visit. Nonetheless, 43.7% of
patients maintained complete pain
remission in the tacrolimus group. In
the clobetasol group, the proportion of
patients with mild symptoms/signs for
all parameters appeared to be greater at
the end of treatment (week 4) and at the
follow-up visit (week 6) than at base-
line. The 4- and 6-week median pain
and mucosal lesion extension scores
were significantly lower than baseline
median scores (po0.001). Only one
patient (6.3%) achieved complete remis-
sion of pain at 4 weeks and no patient
achieved complete remission of burning
sensation and mucosal extension.
Furthermore, at the follow-up visit
(week 6) in the clobetasol group, there
was a slight, but statistically significant,
increase of the median severity scores
for all the three measured symptoms/
signs (po0.05) versus end of treatment
(week 4). Importantly, at the end of
treatment and at the follow-up evalua-
tion, median pain, burning sensation,
and mucosal extension symptom scores
were significantly lower in the tacroli-
mus group compared with the clobetasol
group (po0.001).
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Tolerability
No significant changes in haematolo-
gical and biochemical measures after
4 weeks of treatment were observed in
either group and no severe adverse
events were reported in either treatment
group. In the group treated with tacro-
limus, nine of 16 patients (56.3%)
reported an initial worsening of burning
sensation during the first 2 days of
treatment. However, it resolved rapidly
within 4–5 days as OLP improved. No
oral candidiasis was clinically or micro-
biologically observed in either group.
After 4 weeks of treatment, all patients
treated with tacrolimus had undetectable
(o1.5 pg/l) serum concentrations of
tacrolimus and its metabolites.
Discussion
In this study, topical tacrolimus 0.1%
ointment was significantly more effec-
tive than topical clobetasol propionate
0.05% ointment for treatment of OLP.
All the patients treated with tacrolimus
0.1% or clobetasol propionate 0.05%
ointment had an improvement in symp-
toms. Moreover, a substantial propor-
tion of subjects treated with topical
tacrolimus 0.1% ointment achieved com-
plete remission of symptoms (68.8%,
93.7%, and 56.3% for pain, burning
sensation, and mucosal extension,
respectively), while only one patient
(6.3%) treated with clobetasol achieved
complete remission of pain and no
patients treated with clobetasol had
complete remission of burning sensation
or mucosal lesion extension.
OLP is a chronic inflammatory muco-
cutaneous disease. The involvement
of mucous membranes is frequent, but
usually asymptomatic. However, muco-
sal involvement is occasionally compli-
cated by extensive, painful erosions,
causing a considerable decrease in
quality of life. The oral mucosa, as
well as the genital mucosa, conjunctiva,
oesophagus, larynx, and anus, may be
affected. In contrast to cutaneous lesions,
erosive mucosal lichen planus is highly
resistant to topical treatment and tends
to have a chronic course with little
tendency for spontaneous resolution.
Erosive mucosal lichen planus is reported
to have a slightly increased risk of
malignant transformation (Setterfield
et al. 2000, Edwards & Kelsch 2002,
Eisen 2002, de Moura Castro Jacques
et al. 2003, Eisen 2003, Dissemond
2004, DeRossi & Ciarrocca 2005, Lodi
et al. 2005). Clobetasol propionate has
been reported to be effective in some
open trials in the treatment of OLP
(Lozada-Nur et al. 1991, Campisi et al.
2004). More recently, a placebo-
controlled trial compared clobetasol
0.05% ointment with fluocinonide
0.05% ointment in combination with
antimycotic treatment, consisting of
miconazole gel and 0.12% chlorhexi-
dine mouthwashes. The results sug-
gested that clobetasol was superior to
fluocinonide in controlling OLP in
most cases, without significant adrenal
suppression or other adverse effects.
Moreover, a concomitant antimycotic
treatment with miconazole gel and
chlorhexidine mouthwashes is a useful
and safe prophylaxis against oropharyn-
geal candidiasis (Carbone et al. 1999).
The usual treatment period with clobe-
tasol is 2 weeks. However, longer treat-
ment periods have been proposed for
refractory disease (Edwards & Kelsch
2002). Therefore, in order to attempt
complete remission of symptoms, we
choose a longer treatment period of
4 weeks. Some studies reported that
topical tacrolimus is effective for the
treatment of OLP (Olivier et al. 2002,
Byrd et al. 2004, Laeijendecker et al.
2006). Laeijendecker et al. (2006) treated
patients affected by OLP with tacrolimus
0.1% ointment, and found a relapse of
symptoms in 13 of 18 patients within
3–9 weeks of treatment cessation.
Our trial further supports these obser-
vations and suggests that topical tacro-
limus treatment may be more efficacious
than high-potency topical corticoster-
oids (Kaliakatsou et al. 2002, Corrocher
et al. 2006, Shichinohe et al. 2006).
However, an abrupt discontinuation
of topical corticosteroids may have
resulted in some rebound effect in the
clobetasol group during the follow-up
period. On the other hand, the therapy
with tacrolimus was clearly more effi-
cacious than clobetasol during the treat-
ment period.
The principal limitation of this study
is the short duration of the treatment
period, which was too brief to identify
possible adverse events due to long-term
use of the tacrolimus. It should be
emphasized that a substantial proportion
of patients in the tacrolimus group
(9/16) had a diffuse sensation of oral
Table 1. Number and percentage of patients with various severity scores for pain, burning
sensation, and mucosal extensionw among patients receiving tacrolimus 0.1% (0.2mg) or
clobetasol 0.05% (1.0mg) QD, for 4 weeks, for the treatment of oral lichen planus
Symptoms/signs
and severity score
Tacrolimus (n5 16) Clobetasol (n5 16)
baseline
(week 0)
end of
treatment
(week 4)
follow-up
(week 6)
baseline
(week 0)
end of
treatment
(week 4)
follow-up
(week 6)
Pain
3 (severe) 12 (75.0%) 0 0 12 (75.0%) 0 0
2 (moderate) 4 (25.0%) 0 0 4 (25.0%) 5 (31.2%) 9 (56.3%)
1 (mild) 0 5 (31.2%) 9 (56.3%) 0 10 (62.5%) 7 (43.7%)
0 (absent) 0 11 (68.8%) 7 (43.7%) 0 1 (6.3%) 0
Median score (range) 3 (2–3) 0 (0–1)n 1 (0–1)n,# 3 (2–3) 1 (0–2)n,§ 2 (1–2)n,#,§
Burning sensation
3 (severe) 11 (68.8%) 0 0 11 (68.8%) 0 0
2 (moderate) 5 (31.2%) 0 0 5 (31.2%) 1 (6.3%) 7 (43.7%)
1 (mild) 0 1 (6.3%) 1 (6.3%) 0 15 (93.7%) 9 (56.3%)
0 (absent) 0 15 (93.7%) 15 (93.7%) 0 0 0
Median score (range) 3 (2–3) 0 (0–1)n 0 (0–1)n 3 (2–3) 1 (1–2)n,§ 1 (1–2)n,#,§
Mucosal extension
3 (severe) 13 (81.3%) 0 0 13 (81.3%) 0 0
2 (moderate) 3 (18.7%) 0 0 3 (18.7%) 2 (12.5%) 9 (56.3%)
1 (mild) 0 7 (43.7%) 7 (43.7%) 0 14 (87.5%) 7 (43.7%)
0 (absent) 0 9 (56.3%) 9 (56.3%) 0 0 0
Median score (range) 3 (2–3) 0 (0–1)n 0 (0–1)n 3 (2–3) 1 (1–2)n,^ 2 (1–2)n,#,§
Adverse events 0 9 (56.3%) 0 0 0 0
npo0.001 versus baseline by Wilcoxon’s signed-rank test.
#po0.05 versus end of treatment by Wilcoxon’s signed-rank test.
§po0.001 versus tacrolimus by Mann–Whitney test.
^po0.01 versus tacrolimus by Mann–Whitney test.
wSeverity score indicates the affected percentage of the whole surface of the gingival mucosa,
ranging from 0 to 3: 05 absent; 15 involvement ofo5% of surface (mild); 25 5–15% (moderate);
and 35415% (severe).
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mucosal burning at the beginning of
treatment. However, this sensation was
transient and well tolerated. Indeed, it
was reported only during the first 2 days
of treatment and was resolved rapidly
within 4–5 days as OLP improved.
Another limitation of our study is the
lack of a placebo control group. In this
regard, the Human Subjects Committee
of the Institutional Review Board of
the Dipartimento di Medicina Clinica e
Sperimentale of University of Verona
would not approve the use of a placebo
in these patients because the study had
no provision for rescue medication.
Moreover, a previous study (Carbone
et al. 1999) demonstrated that topical
steroids were beneficial in treating OLP
and withholding effective therapy would
not be ethical.
In conclusion, the results of this clin-
ical trial suggest that topical tacrolimus
0.1% ointment is more effective than
clobetasol propionate 0.05% ointment in
the treatment of OLP. However,
additional larger studies, with a longer
treatment period and follow-up, are
needed to confirm these findings before
the use of tacrolimus ointment can be
recommended in daily clinical practice.
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Clinical Relevance
Scientific rationale for the study:
OLP is a chronic inflammatory dis-
ease, characterized by local pain and
burning sensation. Therapeutic
options include high-potency topical
corticosteroids and the use of immu-
nosuppressive drugs.
Principal findings: In this study,
topical 0.1% tacrolimus ointment
was significantly more effective
than topical 0.05% clobetasol oint-
ment in relieving patient symptoms.
All patients treated with tacrolimus
or clobetasol had an improvement in
symptoms and a substantial propor-
tion of subjects treated with tacroli-
mus achieved complete remission of
symptoms.
Practical implications: Topical
tacrolimus appeared to be more
effective than topical clobetasol for
the treatment of OLP, but larger
studies with more subjects, a longer
treatment period, and longer follow-
up are needed before the use of
tacrolimus ointment can be recom-
mended in clinical practice.
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